These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15785750)

  • 1. The role of dendritic cell precursors in tumour vasculogenesis.
    Coukos G; Benencia F; Buckanovich RJ; Conejo-Garcia JR
    Br J Cancer; 2005 Apr; 92(7):1182-7. PubMed ID: 15785750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of vascular leukocytes in ovarian cancer neovascularization.
    Balint K; Conejo-Garcia JR; Buckanovich R; Coukos G
    Adv Exp Med Biol; 2008; 622():273-80. PubMed ID: 18546635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular leukocytes contribute to tumor vascularization.
    Conejo-Garcia JR; Buckanovich RJ; Benencia F; Courreges MC; Rubin SC; Carroll RG; Coukos G
    Blood; 2005 Jan; 105(2):679-81. PubMed ID: 15358628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis.
    Gottfried E; Kreutz M; Haffner S; Holler E; Iacobelli M; Andreesen R; Eissner G
    Scand J Immunol; 2007 Apr; 65(4):329-35. PubMed ID: 17386023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cells functioning in tumor vascularization as a novel therapeutic target.
    McLean K; Buckanovich RJ
    Transl Res; 2008 Feb; 151(2):59-67. PubMed ID: 18201673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer.
    Coukos G; Conejo-Garcia JR; Buckanovich R; Benencia F
    Adv Exp Med Biol; 2007; 590():185-93. PubMed ID: 17191386
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.
    Conejo-Garcia JR; Benencia F; Courreges MC; Kang E; Mohamed-Hadley A; Buckanovich RJ; Holtz DO; Jenkins A; Na H; Zhang L; Wagner DS; Katsaros D; Caroll R; Coukos G
    Nat Med; 2004 Sep; 10(9):950-8. PubMed ID: 15334073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
    van Kempen LC; Leenders WP
    Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of endothelial progenitor cells in tumour vasculogenesis.
    Ding YT; Kumar S; Yu DC
    Pathobiology; 2008; 75(5):265-73. PubMed ID: 18931528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy.
    Brostjan C; Bayer A; Zommer A; Gornikiewicz A; Roka S; Benkö T; Yaghubian R; Jakesz R; Steger G; Gnant M; Friedl J; Stift A
    Cancer; 2003 Nov; 98(10):2291-301. PubMed ID: 14601101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vascular endothelial growth factor. From basic research to clinical application].
    Smirne C; Camandona M; Rosso E; Bellone G; Emanuelli G
    Minerva Med; 1999; 90(1-2):15-23. PubMed ID: 10388459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the role of angiogenesis and vasculogenesis in solid tumour growth.
    Stamper IJ; Byrne HM; Owen MR; Maini PK
    Bull Math Biol; 2007 Nov; 69(8):2737-72. PubMed ID: 17874270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer dendritic cells are an intermediate of developing dendritic cells.
    Chen L; Calomeni E; Wen J; Ozato K; Shen R; Gao JX
    J Leukoc Biol; 2007 Jun; 81(6):1422-33. PubMed ID: 17332372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization.
    Li B; Sharpe EE; Maupin AB; Teleron AA; Pyle AL; Carmeliet P; Young PP
    FASEB J; 2006 Jul; 20(9):1495-7. PubMed ID: 16754748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-endothelial cell cross-talk in angiogenesis.
    Sozzani S; Rusnati M; Riboldi E; Mitola S; Presta M
    Trends Immunol; 2007 Sep; 28(9):385-92. PubMed ID: 17692569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laminin alpha2 chain (merosin M chain) distribution and VEGF, FGF(2), and TGFbeta1 gene expression in angiogenesis of supraglottic, lung, and breast carcinomas.
    Vitolo D; Ciocci L; Cicerone E; Rossi C; Tiboni F; Ferrauti P; Gallo A; Baroni CD
    J Pathol; 2001 Sep; 195(2):197-208. PubMed ID: 11592099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy.
    Denekamp J
    Br J Radiol; 1993 Mar; 66(783):181-96. PubMed ID: 7682469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human myeloid dendritic cells for cancer therapy: does maturation matter?
    Skalova K; Mollova K; Michalek J
    Vaccine; 2010 Jul; 28(32):5153-60. PubMed ID: 20665974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour vascularisation: a druggable target.
    Bishop-Bailey D
    Curr Opin Pharmacol; 2009 Apr; 9(2):96-101. PubMed ID: 19056315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
    Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.